LMK-235

Catalog No.S7569

For research use only.

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

LMK-235 Chemical Structure

CAS No. 1418033-25-6

Selleck's LMK-235 has been cited by 29 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Other HDAC Products

Biological Activity

Description LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
Targets
HDAC5 [1]
(Cell-free assay)
HDAC4 [1]
(Cell-free assay)
4.2 nM 11.9 nM
In vitro

LMK-235 causes HDAC inhibition with IC50 of <1 μM in human cancer cell lines with different sensitivity towards cisplatin. In breast cancer cell line MDA-MB-231, tongue cancer cell line Cal27, and esophagus cell line Kyse510 cell line, LMK-235 displays a high cytotoxicity, and markedly enhances the cytotoxicity of cisplatin. [1] In addition, LMK-235 also shows nanomolar activity against multiple malaria parasite life cycle stages. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A2780 NFL1ZoNEgXSxdH;4bYNqfHliYYPzZZk> NHnmWZQ4OiCqcoO= NXvVfnZSS3m2b4TvfIlkcXS7IHHnZYlve3RiY3nzdIxifGmwIILld4l{fGGwdDDoeY1idiCDMke4NEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwM{NOwG0> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3Mk[wN{c,OjN{NUK2NFM9N2F-
A2780 MX7GeY5kfGmxbjDhd5NigQ>? MWqxPEBpenN? NX:0Z4hjUW6qaXLpeIlwdiCxZjDISGFEKGmwIHPpd5Bt[XSrbjDy[ZNqe3SjboSgbJVu[W5iQUK3PFAh[2WubIOgZYZ1\XJiMUigbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1yLkOy{txO NV34dXV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVI3ODNpPkKzNlUzPjB|PD;hQi=>
DLD1 MoHwSpVv[3Srb36gZZN{[Xl? M{\3UFEhfG9iMUCgeW0> M{i3WlI1KGi{cx?= MmrNTY5pcWKrdHnvckBw\iCYUGOzOEBqdiCqdX3hckBFVERzIHPlcIx{KGG|c3Xzd4VlKGG|IIDy[ZZmdnSrb36gc4YhVkORQUSgdJJwfGWrbjDk[Ydz[WSjdHnvckBifCBzIITvJFExKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NGniT489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
DLD1 MUjGeY5kfGmxbjDhd5NigQ>? MXqxJJRwKDFyIIXN M4DyXVI1KGi{cx?= MXHJcohq[mm2aX;uJI9nKF[SU{O0JIlvKGi3bXHuJGRNTDFiY3XscJMh[XO|ZYPz[YQh[XNicILleoVvfGmxbjDv[kBxPjJiZHXndoFl[XSrb36gZZQhOSC2bzCxNEB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M1nKZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
DLD1 NHHrWGtHfW6ldHnvckBie3OjeR?= NES2cVEyKHSxIEGwJJVO MmmzNlQhcHK| NXLIN|B5UW6qaXLpeIlwdiCxZjDWVHM{PCCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJJBz\X[nboTpc44hd2ZiTlLSNUBxem:2ZXnuJIRm\3KjZHH0bY9vKGG2IEGgeI8hOTBidV2gbY5kfWKjdHXkJIZweiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz Mlj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ|MkWyOlA{RC:jPh?=
DLD1 NV7INVl6TnWwY4Tpc44h[XO|YYm= MmX5NUB1dyBzMDD1US=> NVmzNJB5OjRiaILz M3XDfmlvcGmkaYTpc44hd2ZiVmDTN|QhcW5iaIXtZY4hTEyGMTDj[YxteyCjc4Pld5Nm\CCjczDwdoV3\W62aX;uJI9nKE6GUEWyJJBzd3SnaX6g[IVoemGmYYTpc44h[XRiMTD0c{AyOCC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MnPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ|MkWyOlA{RC:jPh?=
DLD1 MornSpVv[3Srb36gZZN{[Xl? NEDxNXQyKHSxIEGwJJVO MoPFNlQhcHK| MXnJcohq[mm2aX;uJI9nKF[SU{O0JIlvKGi3bXHuJGRNTDFiY3XscJMh[XO|ZYPz[YQh[XNicILleoVvfGmxbjDv[kBHXEhzIIDyc5RmcW5iZHXndoFl[XSrb36gZZQhOSC2bzCxNEB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? Mnv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ|MkWyOlA{RC:jPh?=
A2780 M33te2N6fG:2b4jpZ4l1gSCjc4PhfS=> NH:yOoQ4OiCqcoO= Mnf3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQ6|ryP MoW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ|MkWyOlA{RC:jPh?=
A2780 NYOybY5wTnWwY4Tpc44h[XO|YYm= NWTlWFQ3OThiaILz NUTkPHhUUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEF{N{iwJINmdGy|IHHmeIVzKDF6IHjyd{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVA:OC54Nd88US=> NFfiOmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
KYSE-510 NIrJOVVHfW6ldHnvckBie3OjeR?= NFWwOXQyQCCqcoO= Mn7yTY5pcWKrdHnvckBw\iCKRFHDJIlvKGOrc4DsZZRqdiC|ZX7zbZRqfmViaIXtZY4hU1mVRT21NVAh[2WubIOgZYZ1\XJiMUigbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1zzszN M37jWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
CAL27 M1vDe2N6fG:2b4jpZ4l1gSCjc4PhfS=> NGnhWlk4OiCqcoO= M1uzdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGOrc4DsZZRqdiC|ZX7zbZRqfmViaIXtZY4hS0GOMkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yNjB|zszN NFLGO5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1NlYxOyd-MkOyOVI3ODN:L3G+
MDA-MB-231 M1nNXGN6fG:2b4jpZ4l1gSCjc4PhfS=> NYX4Umg4PzJiaILz M4flPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGOrc4DsZZRqdiC|ZX7zbZRqfmViaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuN|fPxE1? M4r6SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
MDA-MB-231 Mk\FR5l1d3SxeHnjbZR6KGG|c3H5 NUTIXGlyPzJiaILz NXjLcFh6S3m2b4TvfIlkcXS7IHHnZYlve3RiY3nzdIxifGmwIILld4l{fGGwdDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU43QM7:TR?= MoT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ|MkWyOlA{RC:jPh?=
CAL27 MneyR5l1d3SxeHnjbZR6KGG|c3H5 MonGO|IhcHK| MnHsR5l1d3SxeHnjbZR6KGGpYXnud5Qh[2m|cHzheIlvKHKnc3nzeIFvfCCqdX3hckBESUx{NzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvQDIQvF2= M173fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkWyOlA{Lz5{M{K1NlYxOzxxYU6=
KYSE-510 NWPkeWtjS3m2b4TvfIlkcXS7IHHzd4F6 MXq3NkBpenN? Mo\IR5l1d3SxeHnjbZR6KGGpYXnud5Qh[2m|cHzheIlvKHKnc3nzeIFvfCCqdX3hckBMYVOHLUWxNEBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTJwNElOwG0> MknpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ|MkWyOlA{RC:jPh?=
KYSE-510 NYHyPJVNS3m2b4TvfIlkcXS7IHHzd4F6 MWS3NkBpenN? M135OmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGOrc4DsZZRqdiC|ZX7zbZRqfmViaIXtZY4hU1mVRT21NVAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{Lkm2{txO MlztQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUK2NFMoRjJ|MkWyOlA{RC:jPh?=
HepG2 NGDlbJFCdnSrbXHsZZJq[WxiYYPzZZk> MnXROFghcHK| M3zndWFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KGW6bz3ldpl1cHKxY4n0bYMh\m:{bTDv[kBRdGG|bX;kbZVuKGKncnfo[YkhcW6oZXP0[YQhcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPDhiaILzMEBKSzVyPUCuNVbPxE1? MojsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MES5OlcoRjJ2OUC0PVY4RC:jPh?=
HepG2 M3e1OGN6fG:2b4jpZ4l1gSCjc4PhfS=> NFW0V2o1QCCqcoO= NWnjZWlIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPDhiaILzMEBKSzVyPUGuNlbPxE1? NEHZRmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFk3Pyd-MkS5NFQ6Pjd:L3G+

Protocol (from reference)

Kinase Assay:

[1]

  • HDAC IC50 Profiling:

    The in vitro inhibitory activity of compounds against seven human HDAC isoforms (1, 2, 4 C2A, 5 C2A, 6, 8, and 11) are performed with a fluorescent based assay according to the company’s standard operating procedure. The IC50 values are determined using 10 different concentrations with 3-fold serial dilution starting at 10 μM. TSA and vorinostat are used as reference compounds.

Cell Research:

[1]

  • Cell lines: A2780, Cal27, Kyse510, and MDA-MB-231 cell lines
  • Concentrations: ~10 μM
  • Incubation Time: 72 hours
  • Method:

    The rate of cell survival under the action of test substances is evaluated by an improved MTT assay. The assay is based on the ability of viable cells to metabolize yellow MTT to violet formazan that can be detected spectrophotometrically. In brief, A2780, Cal27, Kyse510, and MDA-MB-231 cell lines are seeded at a density of 5000, 7000, 8000, and 10 000 cells/well in 96-well plates. After 24 h, cells are exposed to increased concentrations of the test compounds. Incubation is ended after 72 h, and cell survival is determined by addition of MTT solution (5 mg/mL in phosphate buffered saline). The formazan precipitate is dissolved in DMSO. Absorbance s measured at 544 and 690 nm in a FLUOstar microplate reader.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5%DMSO+30%PEG300+5%TW80+ddH2O
For best results, use promptly after mixing.

13mg/mL

Chemical Information

Molecular Weight 294.35
Formula

C15H22N2O4

CAS No. 1418033-25-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CC(=CC(=C1)C(=O)NOCCCCCC(=O)NO)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy LMK-235 | LMK-235 supplier | purchase LMK-235 | LMK-235 cost | LMK-235 manufacturer | order LMK-235 | LMK-235 distributor